Business Merck Reports Strong Q2 Growth Driven by Oncology and Animal Health; FDA Approves First Oral PCSK9 Inhibitor August 4, 2026 Merck & Co., Inc. delivered second-quarter 2026 results that exceeded Wall Street expectations, posting revenue of $16.6 billion and demonstrating continued strength across its oncology portfolio and animal health division.…